Home > Insider Trading > Filing (0001415889-16-006486)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070494	Acadia Pharmaceuticals Inc	ACAD	Pharmaceutical Preparations (2834)	061376651

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1487100	Glenn Baity	3611 Valley Centre Drive, Suite 300 San Diego CA 92130	Evp And Gc	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-07-11	4,057	$6.78	66,978	No	4	M	Direct
Common Stock	Disposition	2016-07-11	4,057	$35.00	62,921	No	4	S	Direct
Common Stock	Acquisiton	2016-07-12	5,298	$6.78	68,219	No	4	M	Direct
Common Stock	Acquisiton	2016-07-12	645	$6.78	68,864	No	4	M	Direct
Common Stock	Acquisiton	2016-07-12	3,375	$6.78	72,239	No	4	M	Direct
Common Stock	Acquisiton	2016-07-12	2,625	$6.78	74,864	No	4	M	Direct
Common Stock	Disposition	2016-07-12	11,943	$35.00	62,921	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2016-07-11	4,057	$0.00	4,057	$6.78
Common Stock	Stock Option (right to buy)	Disposition	2016-07-12	5,298	$0.00	5,298	$6.78
Common Stock	Stock Option (right to buy)	Disposition	2016-07-12	645	$0.00	645	$6.78
Common Stock	Stock Option (right to buy)	Disposition	2016-07-12	3,375	$0.00	3,375	$6.78
Common Stock	Stock Option (right to buy)	Disposition	2016-07-12	2,625	$0.00	2,625	$6.78

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
5,298	2017-03-07	No	4	M	Direct
0	2017-03-07	No	4	M	Direct
0	2017-03-07	No	4	M	Direct
0	2017-03-07	No	4	M	Direct
0	2017-03-07	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015 and amended in May 2016.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.04 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.03 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
25% of the shares subject to the Stock Option vested and became exercisable on March 8, 2008. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.